查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1375928

生物标记临床阶段外包服务市场规模、份额、趋势分析报告：依生物标记类型、治疗领域、最终用途、地区、细分市场、预测，2023-2030

Biomarker Clinical Phase Outsourcing Services Market Size, Share & Trends Analysis Report By Biomarker Type (Predictive Biomarkers, Surrogate Endpoints), By Therapeutic Area, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 195 Pages | 商品交期: 2-10个工作天内

价格

生物标记临床阶段外包服务市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球生物标记临床阶段外包服务市场规模将达到271.7亿美元，复合年复合成长率为20.6%。

生物标记诊断应用的增加、组学技术的快速进步、政府研发（R&D）资金的增加以及向精准医疗的转变是推动市场成长的一些因素。

市场分散，多个主要企业拥有相似的技术力和加工能力。这些公司提供与生物标记测试相关的各种服务，包括测定开发、样本分析、资料解释和临床试验支援。由于品质保证、技术进步、法规合规以及提供高价值和多样化服务的能力等因素，该行业的特点是竞争激烈。

生物标记是个人化医疗的核心，可以实现更好的患者照护和更有效的治疗。因此，向精准医疗的转变也是支撑生物标记检测服务需求、进而促进市场成长的关键因素之一。例如，2022年1月，辉瑞公司和Beam Therapeutics公司宣布达成为期年度的独家合作研究协议，开发罕见遗传疾病的精准医疗。

COVID-19 大流行对市场产生了中等影响。由于旅行限制，COVID-19 大流行的早期阶段对临床试验产生了重大影响，包括涉及生物标记测试服务的临床试验。然而，由于 COVID-19 诊断生物标记的快速开拓，市场已从损失中恢復过来。基于生物标记的测试，例如针对病毒 RNA 的 PCR 检测和检测病毒蛋白的抗原测试，对于识别和追踪病毒至关重要。

生物标记临床阶段外包服务市场报告亮点

  • 按生物标记类型划分，替代终点领域占最大份额，2022 年为 56.0%。该领域的增长是由于对精准医疗的需求不断增长以及使用生物标记分析的临床试验数量的增加所推动的。
  • 以治疗领域来看，肿瘤学占最大份额，2022年将达34.6%。该领域市场份额高的主要原因是用于癌症早期检测和诊断的癌症生物标记的需求不断增加。
  • 随着越来越多的生物製药公司投资开发新型生物标记测试服务，预计生技公司在分析期间的年复合成长率将达到 20.8%。
  • 预计亚太地区在预测期内年复合成长率最高，达 21.4%。高成长主要是由于越来越多的西方製药公司将其製造活动外包给中国和印度等新兴经济体。

目录

第1章调查方法和范围

第2章执行摘要

第3章生物标记临床阶段外包服务市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 生物标记临床阶段外包服务市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第4章生物标记临床阶段外包服务市场：生物标记类型估算及趋势分析

  • 生物标记临床阶段外包服务市场，依生物标记类型：细分仪表板
  • 按生物标记类型分類的生物标记临床阶段外包服务市场：变异分析

第5章生物标记临床阶段外包服务市场：治疗区域估算与趋势分析

  • 生物标记临床阶段外包服务市场，依治疗领域：细分仪表板
  • 按治疗领域分類的生物标记临床阶段外包服务市场：变化分析

第6章生物标记临床阶段外包服务市场：最终用途估计与趋势分析

  • 生物标记临床阶段外包服务市场，依最终用途：细分仪表板
  • 按最终用途分類的生物标记临床阶段外包服务市场：变化分析

第7章生物标记临床阶段外包服务市场：区域估计与趋势分析

  • 2022 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第8章竞争形势

  • 市场参与企业分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 2022 年公司市场占有率分析
  • 公司简介
    • Laboratory Corporation of America Holdings
    • Parexel International Corporation
    • ICON plc
    • Charles River Laboratories
    • Proteome Sciences
    • Fujirebio
    • WuXi AppTec
    • NorthEast BioAnalytical Laboratories LLC.
    • Celerion
    • GenScript ProBio
Product Code: GVR-4-68040-138-1

Biomarker Clinical Phase Outsourcing Services Market Growth & Trends:

The global biomarker clinical phase outsourcing services market size is expected to reach USD 27.17 billion by 2030, registering a CAGR of 20.6%, according to a new report by Grand View Research, Inc.. Increasing diagnostic applications of biomarkers, rapid advancements in OMICS technologies, a rise in research and development (R&D) funding from the government, and the shift toward precision medicine are a few of the factors driving the growth of the market.

The market is fragmented, with several key players having similar technological and processing capabilities. These companies offer various services related to biomarker testing, including assay development, sample analysis, data interpretation, and clinical trial support. This industry is characterized by intense competition driven by factors such as quality assurance, technological advancements, regulatory compliance, and the ability to offer high-value and diverse services.

Biomarkers are at the core of personalized medicine, enabling better patient care and more effective treatments. Hence, the shift towards precision medicine is another significant factor supporting demand for biomarker testing services, thereby augmenting market growth. For instance, in January 2022, Pfizer Inc. and Beam Therapeutics Inc. announced an exclusive four-year research collaboration agreement to develop precision medicines for rare genetic diseases.

The COVID-19 pandemic moderately impacted the market. The initial phase of the COVID-19 pandemic has significantly affected clinical trials due to travel restrictions, including trials involving biomarker testing services. However, the market recovered from the losses due to the rapid development of biomarkers for COVID-19 diagnosis. Biomarker-based tests, such as PCR assays targeting viral RNA and antigen tests detecting viral proteins, have been crucial for identifying and tracking the virus.

Biomarker Clinical Phase Outsourcing Services Market Report Highlights:

  • Based on biomarker type, the surrogate endpoints segment accounted for the largest share of 56.0% in 2022. The segment's growth is driven by the growing demand for precision medicines and the rise in the number of clinical trials involving the use of biomarker analysis
  • Based on therapeutic area, the oncology segment accounted for the largest share of 34.6% in 2022. High segment shares are majorly due to the increasing demand for cancer biomarkers for early detection and diagnosis of the condition
  • Based on end-use, the biotechnology companies are anticipated to witness the highest CAGR of 20.8% across the analysis timeframe due to the increasing number of biopharmaceutical companies investing in developing novel biomarker testing services
  • Asia Pacific is anticipated to witness the highest CAGR of 21.4% during the forecast time frame. High growth is primarily due to increasing number of Western pharmaceutical companies outsourcing their manufacturing activities to developing economies such as China and India

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Biomarker Type
    • 1.1.3. Therapeutic Area
    • 1.1.4. End-use
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective-1
    • 1.4.2. Objective-2
    • 1.4.3. Objective-3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biomarker Clinical Phase Outsourcing Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing diagnostic applications of biomarkers
      • 3.2.1.2. Rise in R&D funding from the government
      • 3.2.1.3. Rapid advancements in technologies such as genomics, proteomics, and imaging
      • 3.2.1.4. The shift toward precision medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High capital investment
      • 3.2.2.2. Challenges related to quality control
  • 3.3. Biomarker Clinical Phase Outsourcing Services Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biomarker Clinical Phase Outsourcing Services Market: Biomarker Type Estimates & Trend Analysis

  • 4.1. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Segment Dashboard
  • 4.2. Biomarker Clinical Phase Outsourcing Services Market, By Biomarker Type: Movement Analysis
  • 4.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Biomarker Type, 2018 - 2030
    • 4.3.1. Predictive Biomarkers
      • 4.3.1.1. Predictive Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.2. Prognostic Biomarkers
      • 4.3.2.1. Prognostic Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.3. Safety Biomarkers
      • 4.3.3.1. Safety Biomarkers Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 4.3.4. Surrogate Endpoints
      • 4.3.4.1. Surrogate Endpoints Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 5. Biomarker Clinical Phase Outsourcing Services Market: Therapeutic Area Estimates & Trend Analysis

  • 5.1. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Segment Dashboard
  • 5.2. Biomarker Clinical Phase Outsourcing Services Market, By Therapeutic Area: Movement Analysis
  • 5.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
    • 5.3.1. Oncology
      • 5.3.1.1. Oncology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.2. Neurology
      • 5.3.2.1. Neurology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.3. Cardiology
      • 5.3.3.1. Cardiology Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.4. Autoimmune Diseases
      • 5.3.4.1. Autoimmune Diseases Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)
    • 5.3.5. Others
      • 5.3.5.1. Others Biomarker Clinical Phase Outsourcing Services Market, 2018 to 2030 (USD Million)

Chapter 6. Biomarker Clinical Phase Outsourcing Services Market: End-use Estimates & Trend Analysis

  • 6.1. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Segment Dashboard
  • 6.2. Biomarker Clinical Phase Outsourcing Services Market, By End-use: Movement Analysis
  • 6.3. Biomarker Clinical Phase Outsourcing Services Market Estimates & Forecasts, By End-use, 2018 - 2030
    • 6.3.1. Pharmaceutical Companies
      • 6.3.1.1. Pharmaceutical Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
    • 6.3.2. Biotechnology Companies
      • 6.3.2.1. Biotechnology Companies Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Others Biomarker Clinical Phase Outsourcing Services Market 2018 to 2030 (USD Million)

Chapter 7. Biomarker Clinical Phase Outsourcing Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2022 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2022
  • 8.2. Company Profiles
    • 8.2.1. Laboratory Corporation of America Holdings
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Parexel International Corporation
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. ICON plc
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Charles River Laboratories
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. Proteome Sciences
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Fujirebio
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. WuXi AppTec
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. NorthEast BioAnalytical Laboratories LLC.
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. Celerion
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. GenScript ProBio
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Service Benchmarking
      • 8.2.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 North America Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
  • Table 4 North America Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 5 North America Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 6 North America Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 7 U.S. Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 8 U.S. Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 10 Canada Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 11 Canada Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 13 Europe Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
  • Table 14 Europe Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 15 Europe Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 17 UK Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 18 UK Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 19 UK Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 20 Germany Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 21 Germany Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 22 Germany Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 23 France Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 24 France Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 25 France Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 26 Italy Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 27 Italy Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 28 Italy Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 29 Spain Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area type, 2018 - 2030 (USD Million)
  • Table 30 Spain Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 31 Spain Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 32 Denmark Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 33 Denmark Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 34 Denmark Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 35 Sweden Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 36 Sweden Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 37 Sweden Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 38 Norway Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 39 Norway Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 40 Norway Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 45 China Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 46 China Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 47 China Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 48 Japan Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 49 Japan Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 50 Japan Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 51 India Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 52 India Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 53 Australia Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 54 Australia Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 55 Australia Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 57 South Korea Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 60 Thailand Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 61 Thailand Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
  • Table 63 Latin America Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 64 Latin America Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 65 Latin America Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 67 Brazil Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 68 Brazil Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 69 Mexico Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 70 Mexico Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 71 Mexico Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 72 Argentina Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 73 Argentina Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by region, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 79 South Africa Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 80 South Africa Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 85 UAE Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 86 UAE Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 87 UAE Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Biomarker Clinical Phase Outsourcing Services market, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Biomarker Clinical Phase Outsourcing Services market, by Biomarker Type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Biomarker Clinical Phase Outsourcing Services market, by End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Biomarker Clinical Phase Outsourcing Services market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Biomarker Clinical Phase Outsourcing Services Market Biomarker Type outlook: Segment dashboard
  • Fig. 26 Biomarker Clinical Phase Outsourcing Services: Biomarker Type movement analysis
  • Fig. 27 Predictive Biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 28 Prognostic Biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 29 Safety Biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 30 Surrogate Endpoints market, 2018 - 2030 (USD Million)
  • Fig. 31 Biomarker Clinical Phase Outsourcing Services Market Therapeutic Area outlook: Segment dashboard
  • Fig. 32 Biomarker Clinical Phase Outsourcing Services: Therapeutic Area type movement analysis
  • Fig. 33 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 34 Neurology market, 2018 - 2030 (USD Million)
  • Fig. 35 Cardiology market, 2018 - 2030 (USD Million)
  • Fig. 36 Autoimmune Diseases market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Biomarker Clinical Phase Outsourcing Services market End-use outlook: Segment dashboard
  • Fig. 39 Biomarker Clinical Phase Outsourcing Services market: End-use movement analysis
  • Fig. 40 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 41 Biotechnology Companies market, 2018 - 2030 (USD Million)
  • Fig. 42 Others market, 2018 - 2030 (USD Million)
  • Fig. 43 Regional marketplace: Segment dashboard
  • Fig. 44 Regional outlook, 2022 & 2030
  • Fig. 45 North America market, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 47 Canada market, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market, 2018 - 2030 (USD Million)
  • Fig. 49 Germany market, 2018 - 2030 (USD Million)
  • Fig. 50 UK market, 2018 - 2030 (USD Million)
  • Fig. 51 France market, 2018 - 2030 (USD Million)
  • Fig. 52 Italy market, 2018 - 2030 (USD Million)
  • Fig. 53 Spain market, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark market, 2018 - 2030(USD Million)
  • Fig. 55 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 56 Norway market, 2018 - 2030 (USD Million)
  • Fig. 57 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 58 China market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan market, 2018 - 2030 (USD Million)
  • Fig. 60 India market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia market, 2018 - 2030 (USD Million)
  • Fig. 62 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 66 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 68 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 70 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 71 UAE market, 2018 - 2030 (USD Million)
  • Fig. 72 Kuwait market, 2018 - 2030 (USD Million)